Table 2 Adverse effects of mogamulizumab administration.
|  | 0.1 mg/kg (n = 20) | 1.0 mg/kg (n = 19) | Total (n = 39) | |||
|---|---|---|---|---|---|---|
Cases | Events | Cases | Events | Cases | Events | |
AEs | 20 | 198 | 19 | 126 | 39 | 324 |
Related AE | 19 | 65 | 17 | 49 | 36 | 114 |
  Grade 1/2/3/4 | 16/12/6/1 | 34/23/7/1 | 10/14/4/2 | 23/20/4/2 | 26/26/10/3 | 57/43/11/3 |
  *: Overlapping | * |  | * |  | * |  |
decreased lymphocytes | Â | 15 | Â | 11 | Â | 25 |
  Grade 1/2/3/4 |  | 1/10/3/1 |  | 0/7/2/2 |  | 1/17/4/3 |
dermal disorders | Â | 15 | Â | 11 | Â | 26 |
  Grade 1/2/3/4 |  | 9/5/1/0 |  | 5/6/0/0 |  | 14/11/1/0 |
Drug eruption, Grade 2 | Â | Â | Â | 1 | Â | 1 |
Asteatotic eczema, Grade 1 | Â | 1 | Â | Â | Â | 1 |
Erythema, Grade 1 | Â | 1 | Â | Â | Â | 1 |
Papule, Grade 2 | Â | Â | Â | 1 | Â | 1 |
Pruritus, Grade 1 | Â | 1 | Â | Â | Â | 1 |
Rash, Grade 1/2 | Â | 1/4 | Â | 2/3 | Â | 3/7 |
Rash maculo-papular, Grade 1/2/3 | Â | 5/1/1 | Â | 3/1/0 | Â | 8/2/1 |
other adverse effects | Â | Â | Â | Â | Â | Â |
increased alanine aminotransferase, Grade 1/3 | Â | 3/0/1 | Â | Â | 3/0/1 | Â |
decreased appetite, Grade 1 | Â | Â | Â | 1 | Â | 1 |
increased aspartate aminotransferase, Grade 1/3 | Â | 2/0/1 | Â | Â | 2/0/1 | Â |
Hypophosphatasemia, Grade 3 | Â | Â | Â | 1 | Â | 0/0/3 |
increased gamma-glutamyl transferase, Grade 3 | Â | 1 | Â | Â | Â | 0/0/3 |
hypophosphatasemia, Grade 1 | Â | 1 | Â | Â | Â | 1 |